HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.